236 related articles for article (PubMed ID: 20682652)
1. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.
Fuenmayor J; Perez-Vazquez K; Perez-Witzke D; Penichet ML; Montano RF
Mol Cancer Ther; 2010 Aug; 9(8):2175-85. PubMed ID: 20682652
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
3. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
5. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
6. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
7. A functional C5a anaphylatoxin receptor in a teleost species.
Holland MC; Lambris JD
J Immunol; 2004 Jan; 172(1):349-55. PubMed ID: 14688343
[TBL] [Abstract][Full Text] [Related]
8. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.
Penichet ML; Dela Cruz JS; Shin SU; Morrison SL
Hum Antibodies; 2001; 10(1):43-9. PubMed ID: 11455061
[TBL] [Abstract][Full Text] [Related]
9. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
Cho HM; Rosenblatt JD; Kang YS; Iruela-Arispe ML; Morrison SL; Penichet ML; Kwon YG; Kim TW; Webster KA; Nechustan H; Shin SU
Mol Cancer Ther; 2005 Jun; 4(6):956-67. PubMed ID: 15956253
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
[TBL] [Abstract][Full Text] [Related]
11. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
13. The human mast cell line HMC-1 expresses C5a receptors and responds to C5a but not to C5a(desArg).
Werfel T; Oppermann M; Butterfield JH; Begemann G; Elsner J; Götze O; Zwirner J
Scand J Immunol; 1996 Jul; 44(1):30-6. PubMed ID: 8693289
[TBL] [Abstract][Full Text] [Related]
14. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
[TBL] [Abstract][Full Text] [Related]
15. Fifth complement cascade protein (C5) cleavage fragments disrupt the SDF-1/CXCR4 axis: further evidence that innate immunity orchestrates the mobilization of hematopoietic stem/progenitor cells.
Jalili A; Shirvaikar N; Marquez-Curtis L; Qiu Y; Korol C; Lee H; Turner AR; Ratajczak MZ; Janowska-Wieczorek A
Exp Hematol; 2010 Apr; 38(4):321-32. PubMed ID: 20153802
[TBL] [Abstract][Full Text] [Related]
16. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
17. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
18. NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells.
Richards JO; Albers AJ; Smith TS; Tjoe JA
Cancer Immunol Immunother; 2016 Nov; 65(11):1325-1335. PubMed ID: 27573917
[TBL] [Abstract][Full Text] [Related]
19. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
[TBL] [Abstract][Full Text] [Related]
20. C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection.
Kacani L; Bánki Z; Zwirner J; Schennach H; Bajtay Z; Erdei A; Stoiber H; Dierich MP
J Immunol; 2001 Mar; 166(5):3410-5. PubMed ID: 11207298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
